The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways
Exposure to toxic polycyclic aromatic hydrocarbons raises a number of toxic and carcinogenic responses in experimental animals and humans mediated for the most part by the aryl hydrocarbon – or dioxin – receptor (AHR). The AHR is a ligand-activated transcription factor whose central role in the indu...
Saved in:
Published in: | Biochemical pharmacology Vol. 77; no. 4; pp. 713 - 722 |
---|---|
Main Authors: | , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Elsevier Inc
15-02-2009
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Exposure to toxic polycyclic aromatic hydrocarbons raises a number of toxic and carcinogenic responses in experimental animals and humans mediated for the most part by the aryl hydrocarbon – or dioxin – receptor (AHR). The AHR is a ligand-activated transcription factor whose central role in the induction of drug-metabolizing enzymes has long been recognized. For quite some time now, it has become clear that the AHR also functions in pathways outside of its role in detoxification and that perturbation of these pathways by xenobiotic ligands may be an important part of the toxicity of these compounds. AHR activation by some of its ligands participates among others in pathways critical to cell cycle regulation, mitogen-activated protein kinase cascades, immediate-early gene induction, cross-talk within the RB/E2F axis and mobilization of crucial calcium stores. Ultimately, the effect of a particular AHR ligand may depend as much on the adaptive interactions that it established with pathways and proteins expressed in a specific cell or tissue as on the toxic responses that it raises. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Novartis Pharma AG, CH-4132 Muttenz, Switzerland. |
ISSN: | 0006-2952 1873-2968 |
DOI: | 10.1016/j.bcp.2008.08.031 |